Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

Asia Pac IPO & Placement Research, China biotech

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Equity Capital Markets

Sinomab Bioscience Ltd / Equity Capital Markets

SinoMab is a Hong Kong-based biotech company with a focus on mAb-based biologics for the treatment of immunological diseases, launched its book building to raise up to USD 223 million.In our previous note, we have discussed the company’s pipeline, shareholders and investors, we think despite the product innovation, the academic experience and professional standing of its founder, the company will face big challenges to sell its core product SM03. In this insight, we will have a further discussion on the CD22 target on which SM03 functions. We will detail our valuation of the company on a SOTP basis. We discuss our thoughts on the aggressive assumptions used by book runners.

SinoMab is a Hong Kong-based biotech company with a focus on mAb-based biologics for the treatment of immunological diseases, launched its book building to raise up to USD 223 million.In our previous note, we have discussed the company’s pipeline, shareholders and investors, we think despite the product innovation, the academic experience and professional standing of its founder, the company will face big challenges to sell its core product SM03. In this insight, we will have a further discussion on the CD22 target on which SM03 functions. We will detail our valuation of the company on a SOTP basis. We discuss our thoughts on the aggressive assumptions used by book runners.

SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million. 
In this insight, we will cover the company background, the key products that have reached the clinical trial stage, and the company's shareholders and investors.
The company has taken particularly long on the clinical trials for its core product SM03. Its recently assembled management team are hopeful of moving the product to commercialization. Having said that, we note that indications of its pipelines have significant overlaps with each other in the autoimmune segment.

SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million. 
In this insight, we will cover the company background, the key products that have reached the clinical trial stage, and the company's shareholders and investors.
The company has taken particularly long on the clinical trials for its core product SM03. Its recently assembled management team are hopeful of moving the product to commercialization. Having said that, we note that indications of its pipelines have significant overlaps with each other in the autoimmune segment. 

SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy

Hong Kong

Sinomab Bioscience Limited manufactures antibody drugs. The Company researches, develops, and manufactures anti-infective drugs, antitumor agents, and monoclonal antibodies. Sinomab Bioscience markets its products worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Sinomab Bioscience Ltd (3681 HK)

SinoMab (中国抗体) IPO - A Hard Sell

SinoMab is a Hong Kong-based biotech company with a focus on mAb-based biologics for the treatment of immunological diseases, launched its book...

Ke Yan, CFA, FRM

SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy

SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million. In this insight, we...

Ke Yan, CFA, FRM

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)